PDHA1 and acute kidney injury: Kolobova et al. (2001) confirmed that specific site phosphorylation of PDHA1 can inhibit PDHc activity (Kolobova et al., 2001). It has been reported that the phosphorylation level of PDHA1 increased in CLP-AKI model mice (Li et al., 2020). Moreover, Mao et al. found that reducing the phosphorylation level of PDHA1 mitigated LPS-induced endothelial barrier dysfunction (Mao et al., 2022). Therefore, we speculate that inhibition of PDHA1 phosphorylation may be the target of SA-AKI treatment, but there are no relevant research reports at present.